ABSTRACT. HepG2.2.15 cell is a widely used cell model for studying HBV (hepatitis B virus) in vitro. In these cells, the HBV genome is integrated in several sites of HepG2 cellular DNA. These multiple copies may have some influence on the cellular processes. We constructed a new plasmid, pSEH-Flag-HBV, and transfected it into HepG2 cells, and then screened it with hygromycin. We then used ELISA, PCR, and RT-PCR to detect the expression of HBV in these cell lines. A cell line that stably expressed hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) was established. Using Southern blotting analysis, we found that the HBV genome was integrated as a single copy in the cellular DNA. This cell line will be a useful alternative model for HBV studies.
INTRODUCTION
Hepatitis B virus (HBV) is a member of the family Hepadnaviridae and causes acute and chronic liver infection in humans (Lee, 1997) . HBV is difficult to study in the laboratory owing to a lack of robust models with which to research its gene expression, replication, and interaction with host genes. Although chimpanzees can be infected in vivo with HBV and multiplication of an HBV-like virus occurs in woodchucks, ground squirrels, and Peking ducks (Ganem et al., 1982; Halpern et al., 1984; Lindverg et al., 1985) , the use of whole animals is unsuitable for detailed molecular studies. To investigate HBV replication, appropriate in vitro systems imitating the in vivo situation as closely as possible are necessary.
Many efforts have been made to establish a cell system that allows the replication of this virus. The most common of the cell lines established so far, HepG2.2.15, contains two head-totail copies of the HBV genome between the long terminal repeats of the Moloney leukemia virus (Knowles et al., 1980; Sells et al., 1987) . This cell line is based on the human hepatoblastoma cell line HepG2. Another well-characterized cell line that produces stable HBV particles from a chromosomally integrated state is the HB611 cell line, which was established using Huh6-c15 cells with plasmid p3HB-neo and carries 3 tandemly arranged HBV genomes (Ochiya et al., 1989) . To create the HepG2-4A5 cell line, HepG2 cells were transfected with plasmid pSPT1.2 HBV genes carrying a neomycin-resistant gene controlled by the herpes simplex thymidine kinase promoter (Weiss et al., 1996) . Although these tissue culture systems have been helpful for the in vitro production of HBV, they do not allow studies of the regulation of HBV replication because some of them harbor more than one HBV genome, and at present, stable cell lines that express HBV genes have mostly been built with neomycin resistance. The lack of stable HBV-expressing cell lines has limited the study of the relationship between HBV and host genes.
We have established the cell line HepG2-H4, derived from a human hepatocellular carcinoma HepG2 cell line, through transfection with a recombinant plasmid containing 1.3-fold the full-length HBV genome (genotype B). This cell line has been stably maintained, and HBV has been integrated into a single site of the cellular chromosomes. This system provides an opportunity for further study of the life cycle and biology of HBV in vitro.
MATERIAL AND METHODS

Construction of the plasmid vector
A recombinant vector, pSEH-Flag-HBV, was prepared via insertion of HBV DNA containing fragments from a HindIII digest of pcDNA3.1-HBV into the HindIII site in pSEHFlag (provided by Prof. Tongchuan He, University of Chicago, USA), a plasmid carrying the hygromycin gene. A test for the pSEH-Flag-HBV monomer was performed through HindIII digestion of mini-prep DNA. The nucleotide sequence of the DNA fragments inserted into the vector was verified with sequencing.
Transfection and cell culture
The human hepatoblastoma cell line HepG2 was maintained in 10% fetal bovine serum (GIBCO) in HyClone modified Eagle's medium at 37°C in an atmosphere of 5% CO 2 in air. The most suitable concentration of hygromycin (450 µg/mL) was obtained after 10 days of continued administration. HepG2 cells were then seeded on 6-well plates at a density of 1.5 x 10 6 /well. Transfection was accomplished with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer instructions. In each well, 4 µg pSEH-Flag-HBV was transfected. Cells were chosen at 48 h post-transfection with 450 µg/mL hygromycin. Cell colonies were obtained after approximately 14 days of screening and transferred to 96-well plates in the inverted microscope and enlarged in a 35-cm 2 culture flask.
Detection of hepatitis B e antigen (HBeAg) and hepatitis B s antigen (HBsAg) expression
All cell colonies were seeded in 50% cell confluences on a 6-cm dish. Conditioned medium from each cell line was assayed at 450 nm according to supplier recommendations (Shanghai Kehua Bio-Engineering Enzyme Immunoassay kit for hepatitis B e/core [HBe] antigen and surface [HBs] antigen) after 48 h. The absorbance of samples at 450 nm was measured with a Synergy HT Multi-Detection Microplate Reader (BioTeK). Optical density values greater than 2.1-fold the negative control were considered positive. Each sample was repeated in 3 independent experiments.
DNA preparations and polymerase chain reaction (PCR) assay
Cellular genomic DNA was prepared from 10 x 10 6 cells suspended in 1 mL lysis buffer (10 mM Tris-HCl, pH 7.8, 5 M ethylenediaminetetraacetic acid, 0.5% sodium dodecyl sulfate), lysed with 20 µL proteinase K (20 µg/mL; Promega), and incubated at 55°C for 2 h. The DNA was then treated with phenol/chloroform/isoamyl alcohol (25:24:1, v/v/v), precipitated with 75% ethanol, and dissolved in 50 µL double-distilled water. The primers were designed on HBx and hygromycin genes, which amplified fragment lengths of 462 and 347 bp, respectively. The primers for X gene are: HBx-F, 5'-ATGGCTGCTAGGCTGTACTG-3'; HBx-R, 5'-GGCA GAGGTGAAAAAGTTGCA-3') and the primers for hygromycin gene are hygromycin-F, 5'-TTTCGGCTCCAACAATGTCC-3'; hygromycin-R, 5'-AGCTGCATCATCGAAATTGC -3'). PCR was performed under the following conditions: an initial step of 5 min at 95°C, a differential cycle of 45 s at 95°C, 60 s at 55°C, and 60 s at 72°C, followed by a step at 72°C for 5 min for a total of 30 cycles.
RNA preparation and reverse transcriptase PCR assay
Total RNA was isolated using TRIzol according to manufacturer instructions and was treated using a trace DNA Removal Kit (Promega) to eliminate residual DNA. Concentration and purity were then determined spectrophotometrically. The same amount of RNA was reverse transcribed to obtain complementary DNA using a Reverse Transcription System (Promega) according to manufacturer instructions. Primers, positive controls, and reaction conditions were consistent with conventional PCR conditions.
Southern blot analysis of the integration of HBV DNA into the cellular genome
DNA was extracted from the stable cell line and digested with 4 restriction enzymes. All purified DNA samples were electrophoresed through 1.0% agarose gel and transferred to a nylon membrane. Hybridization was performed overnight at 42°C with 1.1-fold full-length HBV DNA with digoxigenin-labeled nick-translation. A 3.5-kb HBV fragment was used as a positive control.
RESULTS
Characterization of the recombinant vector
Reconstructed pSEH-Flag-HBV plasmids (10.9 kb) were run as 2 fragments after HindIII digestion (Figure 1) , which yielded the expected results (6.7 and 4.2 kb). Sequencing results verified that the recombinant plasmid had been successfully constructed (data not shown). 
HBeAg and HBsAg screening of monoclonal cell using enzyme-linked immunosorbent assay
pSEH-Flag-HBV plasmids were transfected into HepG2 cells and screened with 450 µg/mL hygromycin for 14 days. Thirty-seven hygromycin-positive colonies were formed. The conditioned medium of each clone was collected and assayed for HBsAg and HBeAg expression. We found that the HepG2-H4 cell line produced HBsAg and HBeAg stably, and compared with the HepG2.2.15 cell line, HepG2-H4 produced more negative and positive HBsAg and HBeAg (Figure 2 ).
Identification of HBV DNA and RNA in HepG2-H4 cells
To demonstrate that the HepG2-H4 cell line can stably express HBsAg and HBeAg, we checked for the existence of the HBV genome in HepG2-H4 cellular DNA using PCR. We found that both HBV and hygromycin could be amplified with HepG2-H4 cellular DNA ( Figure 3A) . Furthermore, HBV mRNA expression was identified using reverse transcriptase PCR. Both HBV and hygromycin were expressed in HepG2-H4 cells ( Figure 3B ). 
Identification of integration of HBV DNA
To determine the number of copies of HBV DNA integrated into HepG2-H4 chromosomes, total HepG2-H4 cellular DNA was isolated from the lysed cells for Southern blot analysis. As shown in Figure 4 , the samples analyzed were digested with BglII (lane 1), EcoRI (lane 2), SphI (lane 3), and SacI (lane 4). A 3.5-kb fragment of HBV was used as a probe to analyze HBV in HepG2-H4 chromosomes. We determined that the HBV genome was integrated singly into the HepG2-H4 cell line (see Figure 4) . 
DISCUSSION
With the advent of molecular biology, inserting recombinant genes into human hepatocellular carcinoma cells has become a powerful tool for the identification and analysis of the expression of functional gene products. This technique has greatly accelerated the study of HBV. We successfully constructed a hygromycin-resistant cell line stably expressing HBV to ensure genomic continuity after chromosomal integration and the efficient transcription of viral RNA. We have shown herein that a mere 1.3-fold HBV genome is large enough to act as a template for the synthesis of all HBV mRNAs. In the HepG2-H4 cell line, HBsAg and HBeAg can be highly expressed owing to the strong foreign hEFH (Human EF1α/HLTV hybrid) promoter of HBV, which comes from the pSEH-Flag plasmid.
HepG2 cells have been shown to maintain a substantial number of liver-specific functions (Knowles et al., 1980) . The viral genome integrated just 1 copy into HepG2 cell chromosomes in our HepG2-H4 cells, implying that the extraneous HBV DNA integration affects just 1 gene in HepG2-H4 cells, unlike that in HepG2.2.15 cells, in which HBV is integrated into 4 sites in HepG2.2.15 cellular DNA (Sells et al., 1988) . This integration reduces damage to the HepG2 cells by foreign HBV DNA. We intend to study the position of HBV integration into the host genome.
HepG2-H4 cells can be used to test the effects of drugs that could interfere with viral replication. These cells can also serve as an in vitro model for the analysis of gene involvement in HBV disease processes. Thus, compared with other HBV-producing cell lines established thus far, the features of the HepG2-H4 system make it a more effective candidate with which to study HBV.
